Not available
Quote | Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)
Last: | $19 |
---|---|
Change Percent: | 0.0% |
Open: | $19 |
Close: | $19 |
High: | $19.01 |
Low: | $18.98 |
Volume: | 3,963,455 |
Last Trade Date Time: | 11/07/2023 03:00:00 am |
News | Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
2024-01-02 11:12:57 ET Summary Madrigal Pharmaceuticals, Inc. stock has rallied 70% since late October due to a decrease in competitive concerns and a large secondary offering. The company's candidate resmetirom is expected to be the first approved therapy for NASH in March 2024. ...
Message Board Posts | Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)
Subject | By | Source | When |
---|---|---|---|
Good read | Phoenix300 | investorshub | 05/20/2023 1:24:29 AM |
Did you type what you meant? Ocaliva has | DewDiligence | investorshub | 05/19/2023 10:21:16 PM |
Ocaliva is the classic example of a drug | sunspotter | investorshub | 05/19/2023 10:10:05 PM |
FDA_advisory_panel_votes 15-1 against accelerated approval_for Ocaliva in | DewDiligence | investorshub | 05/19/2023 9:38:20 PM |
is it bear time? Or do we go bull? | DewDiligence | investorshub | 05/19/2023 5:45:10 AM |
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share i...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...